Korea Research Institute of BioScience and BioTechnology Patent applications |
Patent application number | Title | Published |
20160097096 | Composition for Detecting Undifferentiated Human Pluripotent Stem Cell, Monoclonal Antibody 6-1 and Use Thereof - The present invention relates to a composition for detecting the undifferentiated human pluripotent stem cells comprising an agent useful for measuring the level of Desmoglein 2 (Dsg 2) mRNA or the protein thereof, a kit for detecting the undifferentiated human pluripotent stem cells comprising the said composition, a method for detecting the undifferentiated human pluripotent stem cells containing the step of measuring the level of Desmoglein 2 mRNA or the protein thereof, a method for evaluating the differentiation of human pluripotent stem cells and thereafter for separating the undifferentiated human pluripotent stem cells, a method for reducing the undifferentiated status of human pluripotent stem cells by inhibiting the expression or activation of Desmoglein 2, and a monoclonal antibody binding specifically to human Desmoglein 2. | 04-07-2016 |
20160095845 | COMPOSITION COMPRISING (S)-(-)-BENPROPERINE FOR PREVENTING OR TREATING CANCER - The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising (S)-(−)-benproperine or a pharmaceutically acceptable salt thereof as an active ingredient, and a method for preventing or treating cancer using the same. | 04-07-2016 |
20160069865 | GM1 GANGLIOSIDOSIS HUMAN CELL MODEL AND USE THEREOF - The present invention relates to a method for preparing a GM1 gangliosidosis human cell model based on induced pluripotent stem cells (iPSCs) and iPSCs originated neural progenitor cells, and a use of the GM1 model above for the development of a GM1 gangliosidosis treating agent. The iPSCs originated from GM1 patient fibroblasts can be differentiated into neural progenitor cells (NPCs) and neurosphere cells that can emulate the characteristics shown in GM1 patient, so that the said cells can be efficiently used for the investigation of intracellular GM1 symptoms such as the GM1 gangliosidosis and lysosome accumulation and the gene expression pattern change. So, the GM1 cell model of the present invention can be efficiently used for the study of GM1 development mechanism and the study for the development of a therapeutic agent for the disease. The present inventors also established the inflammasome inhibitor rhIL1RA or Z-YVAD-FMK by using the above GM1 cell model and further confirmed that it can be efficiently used as a relieving/treating agent of GM1 gangliosidosis. | 03-10-2016 |
20160068580 | METHOD FOR TREATMENT OF GM1 GANGLIOSIDOSIS - The present invention relates to a method for preparing a GM1 gangliosidosis human cell model based on induced pluripotent stem cells (iPSCs) and iPSCs originated neural progenitor cells, and a use of the GM1 model above for the development of a GM1 gangliosidosis treating agent. The iPSCs originated from GM1 patient fibroblasts can be differentiated into neural progenitor cells (NPCs) and neurosphere cells that can emulate the characteristics shown in GM1 patient, so that the said cells can be efficiently used for the investigation of intracellular GM1 symptoms such as the GM1 gangliosidosis and lysosome accumulation and the gene expression pattern change. So, the GM1 cell model of the present invention can be efficiently used for the study of GM1 development mechanism and the study for the development of a therapeutic agent for the disease. The present inventors also established the inflammasome inhibitor rhIL1RA or Z-YVAD-FMK by using the above GM1 cell model and further confirmed that it can be efficiently used as a relieving/treating agent of GM1 gangliosidosis. | 03-10-2016 |
20160067209 | PTEROCARPAN COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC DISEASE OR COMPLICATION THEREOF, OR FOR ANTIOXIDANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT - The present invention relates to novel pterocarpan compound or pharmaceutically acceptable salt thereof and a composition for the prevention or treatment of metabolic disease or complications thereof comprising the same as an active ingredient. The novel pterocarpan compound of the present invention isolated from soybean leaves inhibits α-glucosidase activity and hACAT activity, and suppresses LDL-oxidation efficiently. Therefore, the compound of the present invention not only can be effectively used for the prevention or treatment of metabolic disease or complications thereof but also can be effectively used as an anti-oxidative composition owing to its excellent anti-oxidative activity. | 03-10-2016 |
20160060239 | GERANYL FLAVONOID DERIVATIVE WITH IMPROVED WATER SOLUBILITY, A METHOD FOR PREPARING THE SAME, AND A METHOD FOR TREATING CANCER USING THE SAME - The present invention relates to a novel geranyl flavonoid derivative with improved water-solubility or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a method for treating cancer using the same. Particularly, the novel geranyl flavonoid derivative of the present invention inhibits the expression of STAT3 target protein by suppressing the phosphorylation of STAT3 (Signal Transducers and Activators of Transcription 3) protein, suggesting that it has cancer cell growth inhibiting effect in various cancer cell lines. Also, the compound of the invention has the effect of reducing the size and weight of a tumor significantly in vivo, so that the geranyl flavonoid derivative or the pharmaceutically acceptable salt thereof can be efficiently used for the treatment of cancer. | 03-03-2016 |
20150344874 | Screening method for drug target gene using heterozygous deletion fission yeast strain - The present invention relates to a screening method for a drug target gene by using chemical-genetic profile compendium of the heterozygous deletion fission yeast strain and the comparative genetic analysis using the same. More precisely, the present inventors constructed the chemical-genetic profile compendium for drug candidates from the heterozygous deletion fission yeast strain of | 12-03-2015 |
20150344571 | ANTIBODY BINDING SPECIFICALLY TO HUMAN AND MOUSE L1CAM PROTEIN, AND USE THEREFOR - The present invention relates to a novel antibody specifically binding to human and mouse L1CAM, and more particularly, to an antibody binding to both human and mouse L1CAM with high affinity, which is prepared by modifying a sequence of an L1 cell adhesion molecule (L1CAM)-specific antibody comprising a heavy-chain variable region of SEQ ID NO. 1 and a light-chain variable region of SEQ ID NO. 5, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide, a transformant introduced with the vector, a pharmaceutical composition for preventing or treating cancer comprising the antibody, a method for treating cancer using the antibody, a composition for diagnosing cancer comprising the antibody, a kit for diagnosing cancer comprising the composition, a method for providing information for cancer diagnosis using the antibody, and an antibody-drug conjugate prepared by conjugating a drug to the antibody. | 12-03-2015 |
20150329840 | Novel Gene From Tidal Flat Metagenome And a Novel Protein Displaying Both Phospholipase And Lipase Activities - The present invention relates to a novel gene derived from a tidal flat metagenome, and a novel protein obtained therefrom showing the coactivity of phospholipase and lipase. Specifically, the novel gene isolated from the metagenome library of tidal flat sediments and the protein having phospholipase and lipase activities encoded from the novel gene: are expressed in a water-soluble form to be mass-producible; enable ultra high-purity protein to be obtained through single step purification using an Ni-NTA column; show good activity in the pH range of 5˜10; maintain good low temperature activity and stability up to a temperature of 3° C. to 40° C.; and have high resistance against various organic solvents. Therefore, the novel gene and the protein can be usefully used for various industrial fields such as the purification and conversion of oil and fat, bio-medicine, and fine chemistry. | 11-19-2015 |
20150299733 | Mutant Beta-Glucosidases Having Enhanced Activity and a Method for Producing Bioethanol Using the Same - The present invention relates to beta-glucosidase that is mutated to have enhanced activity, and a method for producing bioethanol using the same. More particularly, the present invention relates to a polynucleotide encoding beta-glucosidase that is mutated to have enhanced activity, beta-glucosidase expressed from the polynucleotide, an expression vector including the polynucleotide, a transformant that is transformed with the expression vector, a method for producing the mutated beta-glucosidase using the transformant, and a method for producing bioethanol using the transformant. The mutant beta-glucosidase of the present invention increases production of glucose much more than the conventional beta-glucosidase, and thus it can be widely used for economic production of bioethanol. | 10-22-2015 |
20150299665 | METHOD FOR REPROGRAMMING OF HUMAN DENTAL PULP CELL USING OCT4 AND SOX2 AND USE THEREOF - The present invention relates to a method for producing endothelial progenitor cells, comprising a method for producing induced pluripotent stem cells by using only Oct4 and Sox2 as a reprogramming factor of human dental pulp cells, and differentiating endothelial progenitor cells from the induced pluripotent stem cells produced by the method for producing induced pluripotent stem cells. Moreover, the present invention relates to a method for producing endothelial cells, comprising differentiating endothelial cells from endothelial progenitor cells produced by the method for producing the endothelial progenitor cells. Additionally, the present invention relates to a method for producing smooth muscle cells, comprising differentiating smooth muscle cells from endothelial progenitor cells produced by the method for producing the endothelial progenitor cells. | 10-22-2015 |
20150265731 | METHOD TO IMPROVE THE TUMOR DIAGNOSTIC EFFICIENCY OF MULTIVALENT LIGANDS BY REGULATING THE STOICHIOMETRIC RATIO BETWEEN INNER SURFACE FUNCTIONALITIES AND LIGAND MOIETIES FOR TUMOR TARGETING - Disclosed herein is a method of improving tumor diagnostic efficiency of multivalent ligands by regulating the stoichiometric ratio between inner surface functionalities and ligand moieties for tumor targeting, and the multivalent ligands for tumor diagnosis. | 09-24-2015 |
20150259312 | NOVEL DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER METASTASIS COMPRISING SAME AS ACTIVE INGREDIENT - The present invention relates to a novel disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof, a method for preparing the same, and a pharmaceutical anticancer or antimetastasis composition comprising the same as an active ingredient. The disubstituted adamantyl derivative of the present invention suppressed accumulation of HIF-1α, inhibiting the expression of the metastasis related protein Twist dose-dependently. Thus, the disubstituted adamantyl derivative of the invention is effective in inhibiting the expressions of the metastasis related proteins, β-catenin and RohA, and the EMT related genes such as MMP2 and MMP9, without cytotoxicity. Therefore, the disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof of the invention can be efficiently used as a pharmaceutical anticancer or antimetastasis composition. | 09-17-2015 |
20150246088 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES CONTAINING QUAMOCLIT ANGULATA EXTRACT - Disclosed are a pharmaceutical composition for treating diabetes and its complications, containing a | 09-03-2015 |
20150182502 | COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING N-METHYLENENAPHTHO[2,1-b]FURAN-2-CARBOHYDRAZIDE DERIVATIVES AS AN ACTIVE INGREDIENT - The present invention relates to ethyl(2-methyl-3{(E)-[(naphtho[2,1-b]furan-2-ylcarbonyl)hydrazono]methyl}-1H-indole-1-yl)acetate, the novel mitosis inhibitor. The said ethyl(2-methyl-3{(E)-[(naphtho[2,1-b]furan-2-ylcarbonyl)hydrazono]methyl}-1H-indole-1-yl)acetate not only induces apoptosis by inhibiting tubulin polymerization in the course of mitosis but also displays an excellent anticancer effect in the multi-drug resistant cancer cells, so that it can be effectively used for the treatment of cell proliferative disease including various cancers. | 07-02-2015 |
20150110815 | DRUG CONJUGATE COMPRISING DRUG LINKED TO HUMAN C-MET ANTIBODY, AND USE THEREFOR - The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual. | 04-23-2015 |
20140371311 | INGENANE-TYPE DITERPENE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING VIRAL INFECTIOUS DISEASES CONTAINING SAME - The present invention relates to an injenane-type diterpene compound derived from | 12-18-2014 |
20140370132 | COMPOSITION CONTAIING JETBEAD EXTRACTS - The present invention relates to a pharmaceutical composition for preventing or treating Parkinson's disease, which comprises, as an active ingredient, a | 12-18-2014 |
20140364492 | PHORBOL TYPE DITERPENE COMPOUND, PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF VIRAL INFECTIOUS DISEASES INCLUDING SAME - The present invention relates to a diterpene compound derived from | 12-11-2014 |
20140248382 | CURCUMINOID-BASED COMPOUND/STEVIOSIDE-CONTAINING COMPLEX FOR THE PREVENTION AND TREATMENT OF AN INFLUENZA VIRUS INFECTION - The present invention relates to a complex comprising a compound of formula (I), or a plant extract comprising the compound or a fraction thereof; and stevioside, or a plant extract comprising the stevioside or a fraction thereof, and relates to a pharmaceutical composition for preventing or treating an influenza virus infection comprising the complex as an active ingredient. Also, the present invention relates to a food composition for preventing or improving an influenza virus infection, a virucidal quasi-drug composition, a virucidal feed additive, and a feed, which comprises the complex as an active ingredient. According to the present invention, the complex comprising a compound of formula (I), or a plant extract comprising the compound or a fraction thereof; and stevioside, or a plant extract comprising the stevioside or a fraction thereof exhibits a virucidal effect and an effect of inhibiting cell degradation against an influenza virus as well as antiviral efficacy in a specific pathogen-free (SPF) chicken, and thus can be usefully used in the prevention and treatment of an influenza virus infection. | 09-04-2014 |
20140242606 | PROBE FOR iFRET AND USE THEREOF - The present invention relates to a probe for iFRET and use thereof. Specifically, the present invention relates to a novel probe for iFRET, a method for preparing the probe for iFRET, a method for searching a target protein-specific binding site or a molecule having the binding site using the probe for iFRET, and a method for imaging the target protein using the probe for iFRET. The probe for iFRET according to the present invention utilizes an amino acid in a protein as a fluorescent donor, unlike the conventional FRET method. Therefore, only one fluorescent material is used, and its emission wavelength is distinct from the intrinsic fluorescence of the protein. Thus, high specificity and sensitivity are ensured, and the quantity, activity and mechanism of various proteins can be analyzed in an easy and accurate manner. | 08-28-2014 |
20140234285 | Method for Therapeutic Angiogenesis - The present invention relates to the E2 | 08-21-2014 |
20140221411 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT - The present invention relates to a 2-hydroxyarylamide derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition for preventing or treating cancer comprising the same as an active ingredient. The 2-hydroxyarylamide derivative prepared by the present invention is excellent in the inhibition of the activity of TMPRSS4 serine protease and the suppression of the infiltration of TMPRSS4-expressed cancer cells, and thus can be useful as a composition for preventing or treating cancer by inhibiting TMPRSS4 over-expressed in cancer cells, particularly, colorectal cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, or stomach cancer cells. | 08-07-2014 |
20140220631 | Rapid Screening Method of Translational Fusion Partners for Producing Recombinant Proteins and Translational Fusion Partners Screened Therefrom - Disclosed are a method for rapid screening of suitable translational fusion partners (TFPs) capable of inducing expression or secretory production of non-producible proteins, which are difficult to produce in conventional recombinant production methods, from a variety of genetic sources, and protein secretion-inducing TFPs obtained using the method. | 08-07-2014 |
20140206103 | Immunochromatography Detection Sensor Comprising Optical Waveguide and a Detection Method Using the Same - The present invention relates to an immunochromatographic detection sensor comprising optical waveguides and a detection method using the same, and more particularly, to an immunochromatographic detection sensor comprising optical waveguides, in which the optical waveguides are provided under the membrane, probe beams transmitted through the optical waveguide maximize the interaction frequency between evanescent wave generated on the surface of the optical waveguide and the colored conjugate in the band formed on the membrane, resulting in the absorbance signal from the colored conjugate being greatly amplified to improve the sample detection sensitivity, and to a detection method using the same. | 07-24-2014 |
20140193431 | ANTI-C-MET ANTIBODY HAVING HGF ACTIVITY AND USE THEREOF - Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met. | 07-10-2014 |
20140179780 | PHARMACEUTICAL COMPOSITION CONTAINING OLEANOLIC ACID ACETATE AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING TLR- OR IL-6-MEDIATED DISEASES - The present invention relates to a pharmaceutical composition including oleanolic acid acetate or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating TLR- and IL-6-mediated diseases, and a pharmaceutical composition including an adzuki bean extract containing the compound or the salt thereof, or a fraction thereof as an active ingredient for preventing or treating TLR- and IL-6-mediated diseases. The adzuki bean extract or the compound of the present invention is derived from a natural resource that has been used as a natural medicine for a long time, and it is widely used for the development of prophylactic or therapeutic agents for TLR- and IL-6-mediated diseases, for example, atopic dermatitis or arthritis. | 06-26-2014 |
20140179622 | NOVEL COMPOUND ISOLATED FROM QUAMOCLIT, AND COMPOSITION FOR PREVENTING OR TREATING DIABETES CONTAINING THE COMPOUND AS AN ACTIVE INGREDIENT - The present invention relates to a novel compound isolated from | 06-26-2014 |
20140170769 | MICROSCOPE APPARATUS FOR DETECTING OR IMAGING PROTEIN USING PROBE FOR INTRINSIC FLUORESCENCE RESONANCE ENERGY TRANSFER AND METHOD FOR DETECTING OR IMAGING PROTEIN USING THE SAME - A microscope apparatus for detecting or imaging a target protein using a probe for intrinsic fluorescence resonance energy transfer (iFRET) according to the present invention comprises: a light irradiation unit that irradiates a first light having a wavelength range for exciting an amino acid in the target protein and a second light having a wavelength range for exciting a fluorescent molecule of the probe for iFRET; an objective lens that allows the lights irradiated from the light irradiation unit to be incident onto a sample into which the probe for iFRET is introduced; and a recognition unit that detects a first light emitting signal generated from the probe for iFRET by irradiating the first light having a wavelength range for exciting an amino acid in the target protein onto the sample and a second light emitting signal generated from the probe for iFRET by irradiating the second light having a wavelength range for exciting a fluorescent molecule of the probe for iFRET onto the sample, wherein the probe for iFRET includes: a binding site specific to a target protein or a molecule which has the binding site; and a fluorescent molecule having an acceptor function with respect to intrinsic fluorescence of the target protein, which are bonded to each other directly or by a linker. | 06-19-2014 |
20140140960 | Plant disease resistance-related gene from soil metagenome and uses thereof - The present invention relates to a recombinant vector containing a plant disease resistance-related 1B8-4-D7 gene from the soil metagenome, a host cell transformed with the recombinant vector, a recombinant protein produced by the transformed host cell, a plant disease resistance enhancer including the transformed host cell or the recombinant protein as an effective component, a method of enhancing resistance against plant pathogens including eliciting induced resistance by treating a plant with a composition including the transformed host cell or the recombinant protein, and a preparation for controlling plant disease including the transformed host cell or the recombinant protein. | 05-22-2014 |
20140093892 | MARKER COMPRISING ANTI-CK8/18 COMPLEX AUTOANTIBODY AND ITS USE FOR DIAGNOSING CANCER - The present invention relates to a cytokeratin 8/18 complex-specific autoantibody or a fragment comprising an antigen-binding site (paratope) thereof, the use thereof in the diagnosis of breast cancer, a polypeptide having an amino acid sequence of an epitope specifically binding to the autoantibody, a composition for diagnosing breast cancer comprising an agent capable of measuring an expression level of the autoantibody or the fragment comprising an antigen-binding site thereof, a hybridoma cell line producing the autoantibody, and a kit for diagnosing breast cancer comprising the composition of the present invention. Further, the present invention relates to a method for diagnosing breast cancer, comprising the step of detecting the cytokeratin 8/18 complex-specific autoantibody or the fragment comprising the antigen-binding site thereof using the composition of the present invention, and a method for screening a therapeutic agent for breast cancer using the autoantibody. | 04-03-2014 |
20140087420 | NOVEL MICROORGANISM RHIZOBIUM SP. KB10 HAVING PROPERTIES OF PROMOTING GROWH OF BOTRYOCOCCUS BRAUNII AND INCREASING FATTY ACID CONTENT - The present invention relates to | 03-27-2014 |
20140072664 | DAPHNE GENKWA EXTRACTS, AND PHARMACEUTICAL COMPOSITION CONTAINING FRACTIONS OF THE EXTRACTS OR COMPOUNDS SEPARATED FROM THE EXTRACTS AS ACTIVE INGREDIENTS FOR PREVENTING OR TREATING ATOPIC DERMATITIS - The present invention relates to a pharmaceutical composition for the prevention or treatment of atopy comprising the extract of | 03-13-2014 |
20140072558 | Activin Receptor Type II B Inhibitors Comprising DLK1 Extracellular Water-Soluble Domain - The present invention relates to an activin receptor type II B (ACVR2B) inhibitor which comprises the delta-like 1 homolog (DLK1) extracellular water-soluble domain. More specifically, the present invention relates to an extracellular soluble domain of DLK1; fragments of the extracellular soluble domain of DLK1; mutants of the extracellular soluble domain of DLK1; a composition for suppressing ligand linkage with the ACVR2B receptor, which includes a fragment of the mutants as an active ingredient; and a pharmaceutical composition for prevention and treatment of diseases which comprises the same. The composition of the present invention competitively binds to the ACVR2B receptor and inhibits the binding of an ACVR2B ligand to the ACVR2B receptor, which inhibits protein signalling associated with such ligands, and will be useful for prevention and treatment of diseases associated therewith. | 03-13-2014 |
20140057909 | Novel Indole Derivative or Pharmaceutically Acceptable Salt Thereof, Preparation Method Thereof, and Pharmaceutical Composition for Preventing or Treating Metabolic Diseases Containing Same as Active Ingredient - The present invention relates to an indole derivative, The indole derivative according to the present invention effectively inhibits the activity of diacylglycerol acyltransferase (DGAT) which induces metabolic diseases, such as obesity, diabetes, hyperlipidemia, or fatty liver and the like in lipid metabolism, thereby effectively regulating lipid metabolism and energy metabolism, and thus can be useful in pharmaceutical compositions for preventing or treating metabolic disease. | 02-27-2014 |
20140024119 | CELL REPROGRAMMING COMPOSITION COMPRISING REX1 AND AN INDUCED PLURIPOTENT STEM CELL PRODUCTION METHOD USING THE SAME - A reprogramming inducing composition including the Rex1 protein or a nucleic acid molecule coding for the Rex1 protein for producing induced pluripotent stem cells from body cells or non-embryonic cells through a reprogramming process. A method for producing induced pluripotent stem cells by using the Rex1 is also disclosed. | 01-23-2014 |
20130323785 | METHOD FOR PRODUCING HUMAN EPIDERMAL GROWTH FACTOR IN LARGE VOLUME FROM YEAST - The present invention relates to a method for producing hEGF (human epidermal growth factor) which has the same activity as the wild form, in high concentration and with a high degree of purity. More specifically, the invention relates to an hEGF expression vector comprising a nucleic acid sequence coding for the polypeptide of sequence number 14; a host cell in which the expression vector has been genetically transformed; and a method for producing hEGF, comprising a step in which the expression vector is created and is genetically transformed in yeast from which the KEX1 gene is lacking. Using the method of the present invention, it is possible to produce a large volume of human derived EGF which has the same size and activity as human derived EGF, and this EGF can be used in various ways such as in medicine and cosmetics. | 12-05-2013 |
20130296459 | MEDICAL ADHESIVE COMPOSITION - The present invention provides a medical adhesive composition containing poly-gamma-glutamic acid or its salt; and sugar or sugar alcohol, which is edible, water-soluble, anionic and biodegradable. The invention also provides a thickener composition containing poly-gamma-glutamic acid, which can be used as a moisture-absorbing agent, a moisturizing agent and a raw material for cosmetic products. | 11-07-2013 |
20130291234 | SALT TOLERANCE SYDBSP GENE DERIVED FROM SYNECHOCYSTIS, AND USES THEREOF - The present invention relates to a gene encoding | 10-31-2013 |
20130283484 | SALT TOLERANCE SYGT GENE DERIVED FROM SYNECHOCYSTIS, AND USES THEREOF - The present invention relates to a gene encoding SyGT ( | 10-24-2013 |
20130245068 | COMPOSITION COMPRISING BENPROPERINE DERIVATIVES AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING ANGIOGENESIS-RELATED DISEASES - The present invention relates to a novel pharmaceutical composition of benproperine derivatives for preventing and treating angiogenesis-related diseases. The benproperine derivatives and pharmaceutically acceptable salts thereof according to the present invention inhibit cancer cell migration and the angiogenesis of vascular endothelial cells, and therefore can be effectively used not only as an anticancer agent, but also as an agent for preventing and treating diseases caused by abnormal angiogenesis, such as diabetic retinopathy and corneal transplant rejection. | 09-19-2013 |
20130244959 | Composition Containing Styraxlignolide A or the Aglycone Thereof as an Active Ingredient for Preventing or Treating Asthma - The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of | 09-19-2013 |
20130237542 | ARYLOXY PHENOXY ACRYLIC COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT - The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases. | 09-12-2013 |
20130224856 | LARGE-SCALE PROPAGATION AND MAINTENANCE METHOD OF EMBRYOID BODIES GENERATED FROM STEM CELLS - The present invention relates to a large-scale propagation and maintenance method of embryoid bodies generated from stem cells. More particularly, the present invention relates to a large-scale propagation and maintenance method of embryoid bodies retaining their intrinsic characteristics for a long period of time, comprising the step of continuously subculturing embryoid bodies that are primarily produced from embryonic stem cells or from induced pluripotent stem cells. According to the method of the present invention, after preparation of embryoid bodies from a limited number of stem cells, large-scale production and maintenance of embryoid bodies can be realized by a simple mechanical subculturing method without the continuous supply of stem cells. | 08-29-2013 |
20130224779 | METHOD FOR LARGE SCALE PREPARATION OF THE ACTIVE DOMAIN OF HUMAN PROTEIN TYROSINE PHOSPHATASE WITHOUT FUSION PROTEIN - The present invention relates to methods for identifying inhibitors or activators of protein tyrosine phosphatase (PTP). In some examples, the methods utilize a PTP active domain with high activity and stability expressed without help of a fusion protein, by using computer based protein structure prediction technique. PTP prepared by the disclosed method may also be used as an antigen protein for the construction of a selective antibody and as a protein for the studies of PTP structure and functions. | 08-29-2013 |
20130212742 | LATICIFEROUS TISSUE-SPECIFIC SRPP PROMOTER FROM HEVEA BRASILIENSIS AND USES THEREOF - A laticiferous tissue-specific SRPP (small rubber particle-associated protein) promoter derived from | 08-15-2013 |
20130210115 | Method for Activating Catalyst Using Photothermal Nanomaterials - Disclosed is a method for activating a catalyst using the photothermal effects of photothermal nanomaterials, and more particularly to a method of activating a catalyst at a temperature, at which the catalyst has low or no activity, by irradiating a catalyst-photothermal nanomaterial composite with light. The method can activate the catalyst by increasing only the temperature around the nanomaterials without substantially changing the temperature of the reaction medium. A catalyst that generally has high activity at room temperature can be activated even at low temperature. Catalysts having high activity only under mild conditions are immobilized on photothermal nanomaterials so that they have activity even under low temperature and extreme conditions. The invention is useful when a catalyst substrate unstable at room temperature is used or a catalytic product unstable at room temperature is produced. | 08-15-2013 |
20130202592 | Composition for the Anti-Cancer Metastasis Containing DLK1-Fc Fusion Protein as an Effective Ingredient - A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis. | 08-08-2013 |
20130202560 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION AND TREATMENT CONTAINING THE C12ORF59 GENE OR PROTEIN AS AN ACTIVE INGREDIENT - As explained hereinbefore, the C12orf59 gene of the present invention suppresses cancer cell invasion and inhibits cancer cell survivability, and the over-expression of C12orf59 protein or a fragment thereof inhibits cancer cell invasion, so that C12orf59 gene or a fragment thereof not only can be effectively used for the pharmaceutical composition for preventing and treating cancer but also can be used as a clinical marker for screening a cancer treatment agent candidate, for diagnosing various cancers or for predicting pathological stage. In addition, the C12orf59 gene or a fragment thereof of the present invention can be used for the method for preventing and treating cancer and for the preparation of a pharmaceutical composition for preventing and treating cancer. | 08-08-2013 |
20130190200 | SNP FOR PREDICTING THE SENSITIVITY TO ANTICANCER TARGETED THERAPEUTIC FORMULATION - The present invention relates to a single nucleotide polymorphism (SNP) for predicting the sensitivity to an anticancer targeted therapeutic formulation, a polynucleotide containing the same, and a method for predicting the sensitivity to an anticancer targeted therapeutic formulation. According to the present invention, it is possible to predict the sensitivity of each individual to a certain anticancer targeted therapeutic formulation, using a small amount of a sample taken from a patient and thus to select a most suitable targeted therapeutic formulation over the entire duration of treatment for the patient. | 07-25-2013 |
20130157262 | Method for Selecting Antibody-Producing Cell Line, and Kit Thereof - Provided is a method for selecting antibody-producing cell lines using a split fluorescent protein, and a kit for selecting antibody-producing cell lines. By using the split fluorescent protein to select the antibody-producing cell lines, the antibody-producing cell lines can be easily detected by observing whether a single fluorescent color derived from reassembly of the split fluorescent proteins is expressed, which leads in a drastic reduction in selection time and cost required to select highly productive antibody-producing cell line. | 06-20-2013 |
20130149374 | Asymmetric Liposomes for the Highly Efficient Encapsulation of Nucleic Acids and Hydrophilic Anionic Compounds, and Method for Preparing Same - The present invention relates to asymmetric liposomes for high encapsulation efficiency of nucleic acids and hydrophilic anionic compounds, and to a method for preparing same, and specifically, to asymmetric liposomes consisting of a cationic lipid having a small head group as an internal lipid and a neutral or PEGylated lipid having a big head group as an external lipid, wherein nucleic acids and/or anionic compounds are encapsulated in the internal lipid. According to the present invention, asymmetric liposomes, in which nucleic acids and hydrophilic anionic compounds are encapsulated with high efficiency, may be prepared, and thus the same may be used for various purposes, such as gene therapy, and the delivery of hydrophilic anionic drugs which are difficult to prepare as prodrugs, and drug delivery, imaging, etc. can be carried out by encapsulating a fluorescent contrast agent in the liposome. | 06-13-2013 |
20130116297 | NOVEL FUSARISETIN COMPOUNDS, AND USE THEREOF - The present invention relates to novel fusarisetin compounds separated from | 05-09-2013 |
20130108652 | ASTHMA DIAGNOSIS USING THE NEUROPILIN-1 GENE, AND METHOD FOR SCREENING FOR A THERAPEUTIC AGENT FOR ASTHMA | 05-02-2013 |
20130089901 | NOVEL THRAUSTOCHYTRID-BASED MICROALGAE, AND METHOD FOR PREPARING BIO-OIL BY USING SAME - The present invention relates to novel thraustochytrid-like microalgae having the ability to produce bio-oil, and a method of producing bio-oil using the same. The microalgae of the invention accumulate bio-oil at a high ratio in the cells when being cultured in glucose-containing medium, and thus can produce bio-oil in a high yield. Also, the microalgae can produce bio-oil using bean powder as a nitrogen source, and a product obtained by culturing edible bean powder as medium can be used as a raw material for producing food and feed. Also, the microalgae can produce bio-oil using non-food cellulosic biomass as a carbon source. Moreover, the use of non-food cellulosic biomass for production of bio-oil can overcome the factors limiting the development of bio-oil, including the unstable supply of food resources and an increase in the cost of raw materials, and can improve the commercial competitiveness of microbial fermentation oil. | 04-11-2013 |
20130065220 | METHOD OF RAPIDLY DETECTING MICROORGANISMS USING NANOPARTICLES - The present invention relates to a method of rapidly detecting microorganisms using nanoparticles, and more particularly to a method and device of rapidly detecting microorganisms by adding, to the microorganisms to be detected, nanoparticles having immobilized thereon an antibody that binds specifically to the microorganisms to be detected, subjecting the mixture to an immune reaction to form a reaction solution, passing the reaction solution through a microorganism-concentrating film to concentrate the microorganisms, capturing microorganisms, which was immune-reacted with the antibody-immobilized nanoparticles, by a microorganism-capturing filtration membrane, and determining the presence and concentration of the microorganisms. | 03-14-2013 |
20130053443 | METHOD FOR PREPARING EXTRACT CONTAINING OMEGA FATTY ACIDS FROM PLANT BY USING SUPERCRITICAL CARBON DIOXIDE EXTRACTION - The present invention relates to a method for preparing an extract containing omega fatty acids from a plant containing omega fatty acids, including the following steps: drying the plant containing omega fatty acids to prepare a powder; and extracting omega fatty acids from the prepared plant powder by using supercritical carbon dioxide as a solvent at an optimum temperature and pressure, a dietary supplement and a cholesterol-lowering pharmaceutical composition containing plant-derived omega fatty acids extracted by the method, and omega fatty acids-containing plant extract containing a predetermined or greater amount of omega-3 fatty acids. | 02-28-2013 |
20130052660 | METHOD FOR DETECTING PROTEIN-PROTEIN INTERACTIONS IN CELLS - The present invention relates to a method for detecting protein-protein interactions in living cells, and more particularly, to a method for providing cells comprising a first construct and a second construct, wherein the first construct comprises a polynucleotide encoding a first fusion protein which comprises a bait protein, a first fluorescent protein and a CBD (cellulose-binding domain) protein, and wherein the second construct comprises a polynucleotide encoding a second fusion protein which comprises a prey protein and a second fluorescent protein so as to allow formation of inclusion bodies, and detecting interactions between the bait protein and the prey protein that are displayed by inclusion bodies, a method for isolating the prey protein bound to the bait protein using the cells comprising the constructs, the cells, and a kit for detecting protein-protein interactions, comprising the constructs. | 02-28-2013 |
20130040366 | METAGENOME-DERIVED ALKALINE PHOSPHATASE - The present invention relates to a metagenome-derived alkaline phosphatase, and more particularly to a novel, metagenome-derived alkaline phosphatase screened using a artificial genetic circuit that detects phenolic compounds, and a preparation method thereof. A novel alkaline phosphatase according to the present invention has high activity of dephosphorylating DNA and can be inactivated rapidly by simple heat treatment. Thus, it can be used for a dephosphorylation reaction so that genetic manipulations, including genetic cloning, become efficient. In addition, it can be actively expressed in recombinant microorganisms, and thus can be used in various assays, including enzyme immunoassay. | 02-14-2013 |
20130022642 | Dual Antagonist for TNF-A and IL-21 for Preventing and Treating Autoimmune Diseases - The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (α) and IL-21. The composition containing the double antagonist to TNF-α and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease. | 01-24-2013 |
20130017226 | TNF-A and TWEAK Dual Antagonist for the Prophylaxis and Treatment of Autoimmune DiseasesAANM Park; Young WooAACI DaejeonAACO KRAAGP Park; Young Woo Daejeon KRAANM Jo; Ki WonAACI Gyeonggi-doAACO KRAAGP Jo; Ki Won Gyeonggi-do KRAANM Yoo; Srok HoAACI DaejeonAACO KRAAGP Yoo; Srok Ho Daejeon KRAANM Yu; JungAACI DaejeonAACO KRAAGP Yu; Jung Daejeon KRAANM Kim; Dong JiAACI DaejeonAACO KRAAGP Kim; Dong Ji Daejeon KRAANM Yoon; Sun-HaAACI DaejeonAACO KRAAGP Yoon; Sun-Ha Daejeon KRAANM Song; Eun JungAACI DaejeonAACO KRAAGP Song; Eun Jung Daejeon KRAANM Lee; Eun KyungAACI Gyeonggi-doAACO KRAAGP Lee; Eun Kyung Gyeonggi-do KRAANM Oh; Jin MiAACI Gyeonggi-doAACO KRAAGP Oh; Jin Mi Gyeonggi-do KRAANM Cho; Kyu WonAACI SeoulAACO KRAAGP Cho; Kyu Won Seoul KRAANM Cho; Mi LaAACI SeoulAACO KRAAGP Cho; Mi La Seoul KRAANM Kim; Ho YounAACI SeoulAACO KRAAGP Kim; Ho Youn Seoul KRAANM Park; Mi KyungAACI Gyeonggi-doAACO KRAAGP Park; Mi Kyung Gyeonggi-do KRAANM Oh; Hye JwaAACI SeoulAACO KRAAGP Oh; Hye Jwa Seoul KRAANM Park; Jin SilAACI SeoulAACO KRAAGP Park; Jin Sil Seoul KRAANM Woo; Yun JuAACI SeoulAACO KRAAGP Woo; Yun Ju Seoul KRAANM Byun; Jae KyeongAACI Chungcheongbuk-doAACO KRAAGP Byun; Jae Kyeong Chungcheongbuk-do KRAANM Ryu; Jun GeolAACI Gangwon-doAACO KRAAGP Ryu; Jun Geol Gangwon-do KR - The present invention relates to TNFR2-TWEAKR fusion protein, more precisely to TNFR2-TWEAKR fusion protein acting as a double-antagonist to TNF-α and TWEAK, known as major causes of autoimmune arthritis which is one of autoimmune diseases. When the composition comprising TNFR2-TWEAKR fusion protein was treated to Th17 cells, the secretion of the inflammatory cytokine IL-17 was reduced but the secretion of the anti-inflammatory cytokine IL-10 generated in Treg cells was increased. Such effect of TNFR2-TWEAKR fusion protein was far greater than that of a single protein such as TNFR2-Fc or TWEAK-Fc. The TNFR2-TWEAKR fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-TWEAKR fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease. | 01-17-2013 |
20130004596 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES CONTAINING QUAMOCLIT ANGULATA EXTRACT - The present invention relates to a pharmaceutical composition for treating diabetes and its complications, containing a | 01-03-2013 |
20120322129 | MODIFIED YEAST STRAIN AND A METHOD FOR PRODUCING SQUALENE USING THE SAME - The present invention relates to a modified yeast strain which is prepared by introducing a vector that expresses HMG-CoA reductase (hydroxymethylglutaryl CoA reductase) and farnesyl pyrophosphate synthase, and a method for producing squalene using the same. More particularly, the present invention relates to | 12-20-2012 |
20120270287 | NOVEL METHOD OF PRODUCING 3-HYDROXYPROPIONIC ACID FROM GLYCEROL - The present invention relates to a novel method of producing 3-hydroxypropionic acid from glycerol, and more particularly to a method of producing 3-hydroxypropionic acid by culturing in a glycerol-containing medium a mutant microorganism obtained by amplifying an aldehyde dehydrogenase-encoding gene in a microorganism having the abilities to produce coenzyme B12 and produce 3-hydroxypropionic acid using glycerol as a carbon source. The present invention enables the fermentation of glycerol even under microaerobic or aerobic conditions without having to add coenzyme B12. Thus, the invention will be very suitable for the development of biological processes for producing large amounts of 3-hydroxypropionic acid. | 10-25-2012 |
20120270235 | MEMBRANE BIOSENSOR HAVING MULTI-HOLE FILM ATTACHED THERETO AND METHOD FOR MEASURING IMMUNOLOGICAL REACTION OR ENZYMATIC REACTION USING THE SAME - The present invention relates to a membrane sensor having a multi-hole film attached thereto and a method for measuring immunological reactions or enzymatic reactions using the same. More specifically, the present invention relates to a membrane sensor in which a multi-hole film is joined to the top of a membrane on which receptors are immobilized, and a method for measuring immunological reactions or enzymatic reactions using the same. The present invention makes it possible to adjust the sensitivity of membrane biosensors by adjusting the hole size in the multi-hole film and so makes it possible to measure analytes with a high degree of sensitivity using just a small amount of sample, and makes it possible to simultaneously measure diverse types of analyte by attaching various types of receptor on the membrane sensor. | 10-25-2012 |
20120264167 | NOVEL GINSENOSIDE GLYCOSIDASE DERIVED FROM THE GENUS TERRABACTER, AND USE THEREOF - The present invention relates to a novel ginsenoside glycosidase protein derived from the genus | 10-18-2012 |
20120264147 | Diagnostic Marker for Hepatocellular Carcinoma Comprising Anti-FASN Autoantibodies and a Diagnostic Composition for Hepatocellular Carcinoma Comprising Antigens Thereof - The present invention relates to an autoantibody specifically recognizing the epitope sequence of FASN (fatty acid synthase), more particularly, to the autoantibody or a fragment comprising an antigen-binding site thereof, a diagnostic composition for hepatocellular carcinoma comprising an agent capable of assessing the expression level of the autoantibody, a hybridoma cell line producing the autoantibody, a diagnostic kit for hepatocellular carcinoma comprising the composition, a method for detecting the autoantibody of hepatocellular carcinoma patient using the composition, and a method for screening a therapeutic agent for hepatocellular carcinoma by administering candidate materials for hepatocellular carcinoma treatment to confirm a reduction in the expression level of autoantibody. | 10-18-2012 |
20120234792 | LITHOGRAPHY METHOD USING TILTED EVAPORATION - The present invention relates to a lithography method using tilted evaporation, and includes: (1) coating a resist on top of a substrate; (2) patterning the resist using a lithography process; (3) tilt-evaporating a first thin film material on an upper layer of the patterned resist to form a modified pattern mask; (4) evaporating a second thin film material on the top of the substrate with the modified pattern mask; and (5) removing the resist coated on the top of the substrate. | 09-20-2012 |
20120230965 | Novel Microorganism Bacillus megaterium Toha Producing L-Type Poly-Gamma-Glutamic Acid and L-Type Poly-Gamma-Glutamic Acid Produced Thereby - The present invention relates to a novel microorganism producing L-type poly-gamma-glutamic acid and an L-type poly-gamma-glutamic acid produced thereby and, more particularly, to | 09-13-2012 |
20120202248 | NOVEL HANSENULA POLYMORPHA GENE CODING FOR DOLICHYL-PHOSPHATE- MANNOSE DEPENDENT ALPHA-1,3 MANNOSYLTRANSFERASE AND PROCESS FOR THE PRODUCTION OF RECOMBINANT GLYCOPROTEINS WITH HANSENULA POLYMORPHA MUTANT STRAIN DEFICIENT IN THE SAME GENE - The present invention relates to a process for producing a human-type glycoprotein having reduced glycosylation by genetically manipulating an enzyme involved in glycosylation using a | 08-09-2012 |
20120201838 | METHOD FOR SCREENING ANTICANCER AGENT OR SIP1/ZEB2 INHIBITOR USING INTEGRIN ALPHA 5 - The present invention relates to a method for screening anticancer agent or SIP1/ZEB2 inhibitor using integrin alpha 5 (ITGA5), more precisely a method for measuring integrin alpha 5 expression pattern in SIP1/ZEB2 over-expressing cell line or SIP1/ZEB2 expression induced cell line, both treated with sample compounds, by comparing with that of the control. The method of the present invention facilitates screening of anticancer agent or SIP1/ZEB2 inhibitor simply by measuring integrin alpha 5 expression, so that it can be effectively applied in the field of medicine. | 08-09-2012 |
20120184499 | PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PSEUDOLYSIMACHION LONGIFOLIUM AND THE CATALPOL DERIVATIVES ISOLATED THEREFROM HAVING ANTIINFLAMMATORY, ANTIALLERGIC AND ANTIASTHMATIC ACTIVITY - The present invention relates to a composition comprising an extract of | 07-19-2012 |
20120183632 | PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PSEUDOLYSIMACHION LONGIFOLIUM AND THE CATALPOL DERIVATIVES ISOLATED THEREFROM HAVING ANTIINFLAMMATORY, ANTIALLERGIC AND ANTIASTHMATIC ACTIVITY - The present invention relates to a composition comprising an extract of | 07-19-2012 |
20120171727 | NOVEL GENOME WALKING METHOD FOR CLONING OF UNKNOWN DNA SEQUENCES ADJACENT TO KNOWN SEQUENCE - A method and a kit for cloning a nucleotide sequence adjacent to a known nucleotide sequence by PCR are disclosed. The method includes 1) preparing a DNA fragment with cohesive ends by cleaving a DNA that contains the known first nucleotide sequence and the second nucleotide sequence adjacent thereto using a restriction enzyme; 2) modifying the 3′ end of the DNA fragment with a nucleotide analogue to block further elongation of the DNA fragment; 3) linking the cohesive ends of the 3′ end-modified DNA fragment with a linker, adapter or cassette having a cohesive end sequence complementary thereto; and 4) performing PCR using a known first nucleotide sequence-specific primer, and a linker, adapter or cassette sequence-specific primer. | 07-05-2012 |
20120164174 | ADJUVANT COMPOSITION CONTAINING POLY-GAMMA-GLUTAMIC ACID-CHITOSAN NANOPARTICLES - The present invention relates to an adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles and a vaccine composition containing the adjuvant composition, and more particularly to an adjuvant composition containing nanoparticles prepared by ionic bonding between poly-gamma-glutamic acid having ensured safety and chitosan, and a vaccine composition containing the poly-gamma-glutamic acid-chitosan nanoparticles and an antigen. The adjuvant containing the poly-gamma-glutamic acid-chitosan nanoparticles has little or no toxicity and side effects and is added to human or animal vaccines for the prevention and treatment of viral and bacterial infections and cancers to increase the production of antibodies. | 06-28-2012 |
20120156172 | NEW LACTIC ACID BACTERIA HAVING ITS INHIBITORY EFFECT ON AVIAN INFLUENZA VIRUS INFECTION AND COMPOSITION CONTAINING THE SAME - The present invention relates to a new microorganism | 06-21-2012 |
20120107297 | Method for therapeutic angiogenesis - The present invention relates to the E2 | 05-03-2012 |
20120088261 | CELL LABELING AND IMAGING USING MULTIFUNCTIONAL PERFLUOROCARBON NANOEMULSION - The present invention relates to cell labeling and imaging using a multifunctional perfluorocarbon (PFC) nanoemulsion. In particular, the perfluorocarbon nanoemulsion containing optical nanoparticle is provided with both optical characteristics and | 04-12-2012 |
20120083048 | METHOD FOR DETECTING LIGAND USING FRET BIOSENSOR - The present application relates to a method for detecting ligand using a biosensor applied the FRET(fluorescence resonance energy transfer) phenomenon. More particularly, the method may be used for simply detecting a ligand in a sample by measuring the FRET of a biosensor under the conditions in which a specific critical temperature is maintained. The method may use a phenomenon in which a ligand-binding protein in a biosensor shows reversible unfolding at a temperature higher than the specific critical temperature and the level of the unfolding changes depending on the concentration of a ligand. The method can be widely applied to a variety of kinds of FRET biosensors using the ligand-binding protein. | 04-05-2012 |
20120059326 | Microneedle Unit Capable of Controlling Fluid Delivery - Provided is a microneedle unit comprising a case having a space accommodating a fluid and a fluid channel through which the fluid is discharged, a microneedle coupled to a lower portion of the case, a base cover disposed at the lower portion of the case, having a hole through which the microneedle passes, and being vertically movable, a guide pin coupled to the base cover and configured to open and close the fluid channel, and an elastic member configured to impart a restoring force such that the base cover is moved upward by an external pressure and then returns downward again. Therefore, the microneedle unit, which is provided to deliver a fluid into the skin with no pain and no scar, can control injection of the fluid using the guide pin, and repeatedly and conveniently control injection of the fluid using the elastic member. | 03-08-2012 |
20120041178 | Coenzyme Q10 Nanoparticles, Preparation Method Thereof and Composition Containing Said Nanoparticles - Provided are a coenzyme Q10 nanoparticle, a method of preparing the same and a composition having the nanoparticle. According to the present invention, Coenzyme Q10 may be dissolved in only a water-miscible organic solvent, and easily made into a nano-sized particle and solubilized under a low energy condition, for example, by simple stirring. The coenzyme Q10 may be dispersion-stabilized by an amino acid or protein. The coenzyme Q10 is formed in a nano-sized particle and solubilized, an absorption rate may be increased and simultaneously deliver the amino acid and protein with the nanoparticle. Thus, the coenzyme Q10 nanoparticle can be effectively used in food, cosmetics and medicine. | 02-16-2012 |
20120010130 | COMPOSITION FOR PREVENTING VIRUS INFECTION COMPRISING POLY-GAMMA-GLUTAMIC ACID - The present invention relates to a pharmaceutical composition for inhibiting or preventing viral infection, which comprises an effective dose of poly-gamma-glutamic acid (γ-PGA), and more particularly, to a pharmaceutical composition, a functional food, and a feedstuff additive capable of inhibiting viral infection and preventing viral diseases, which comprise poly-gamma-glutamic acid having an infection-inhibiting effect against viruses, such as an influenza virus, inducing respiratory infection or systemic infection, as an effective ingredient. | 01-12-2012 |
20110306513 | NOVEL BIOMARKER FOR LIVER CANCER AND APPLICATIONS FOR SAME - The present invention relates to the elucidation of a gene that can act as a novel marker for liver cancer diagnosis and to diagnostic and prognostic measurements of liver cancer using the same. More specifically, it relates to a diagnosis kit that enables diagnostic and prognostic measurement of a liver cancer using a preparation that measures expression levels of at least one gene selected from a group of liver cancer diagnosis markers consisting of S100P, NK4, CCL20, CSPG2, PLAU, MMP12, ESM-1, ABHD7, HCAPG, CXCL-3, Col5A2, MAGEA, GSN, CDC2, CST1, MELK, ATAD2, FAP and MSN and/or a method for diagnostic and prognostic measurement of liver cancer using the same. These have been discovered using normal liver tissues and liver cancer tissues collected from the same liver cancer patient of the present invention and represent the markers whose accuracy and reliability have been greatly improved as markers of liver cancer. The markers of the present invention can be used for the accurate diagnosis and prognosis of liver cancer. | 12-15-2011 |
20110305680 | Composition Containing Osteopontin for Differentiating Natural Killer Cell as an Active Ingredient and a Method of Differentiation Using Thereof - The present invention relates to a composition for differentiating natural killer cells comprising osteopontin (OPN) as an active ingredient and a method for differentiation using the same. More precisely, osteopontin of the present invention accelerates differentiation of natural killer cells from hematopoietic stem cells and increases cytotoxic activity of natural killer cells, so that it can be effectively used as a composition for differentiating natural killer cells. OPN of the present invention regulates differentiation of natural killer cells capable of killing cancer cells, so that it can be effectively used for the treatment of cancer. | 12-15-2011 |
20110293600 | Anticancer Composition Comprising Antitumor Agent and Substance Having Inhibitory Effects on L1CAM Activity and Expression - The present invention relates to an anticancer composition comprising an antitumor agent as well as a substance having inhibitory effects on the activity or expression of L1CAM; more particularly, to an anticancer composition, which comprises an anti-L1CAM antibody specific to L1CAM, serving as a substance for inhibiting the activity of L1CAM; an oligonucleotide inhibiting the generation of L1CAM, serving as a substance for inhibiting the expression of L1CAM; and a substance selected from cisplatin, gemcitabine, 5-fluorouracil and taxol, serving as an antitumor agent. The composition according to the present invention has the benefit of the combined use of a substance having inhibitory effects on the activity or an expression of L1CAM and an antitumor agent concurrently, separately or sequentially so that it demonstrates stronger and more significant pharmaceutical effects than the exclusive use of those substances on inhibiting proliferation and inducing apoptosis in cancer cells, thereby making it very useful for cancer treatment. | 12-01-2011 |
20110287463 | RECOMBINANT BETA-GALACTOSIDASE DERIVED FROM STREPTOCOCCUS PNEUMONIAE - The present invention relates to a novel beta-galactosidase derived from | 11-24-2011 |
20110251097 | DIAGNOSTIC KIT OF COLON CANCER USING COLON CANCER RELATED MARKER AND DIAGNOSTIC METHOD THEREOF - The present invention relates to a composition for diagnosing colon cancer. The composition comprises at least one marker for measuring an mRNA or protein expression level of at least one gene specific for colon cancer. It can screen the genes which are overexpressed specifically only in colon cancer tissues or blood. The present invention can quantitatively analyze both the mRNA expression levels of the genes and the expression levels of the proteins encoded by the gene at the same time, thereby diagnosing colon caner of an early stage with a high level of reliability. | 10-13-2011 |
20110223118 | ANTIBACTERIAL PHARMACEUTICAL COMPOSITION COMPRISING ACERIPHYLLUM ROSSII EXTRACT AND ACTIVE COMPOUNDS ISOLATED THEREFROM - The present invention relates to an antibacterial pharmaceutical composition comprising an | 09-15-2011 |
20110213016 | E2EPF Ubiquitin Carrier Protein-Von Hippel-Lindau Interaction and Uses Thereof - The present invention relates to the E2 | 09-01-2011 |
20110212032 | POLYMER PARTICLES FOR NIR/MR BIMODAL MOLECULAR IMAGING AND METHOD FOR PREPARING THE SAME - The present invention relates to polymer particles showing magnetic properties and fluorescent properties simultaneously and a preparation method thereof More specifically, relates to polymer particles for near infrared (NIR)/magnetic resonance (MR) bimodal molecular imaging, contain a magnetic nanomaterial and an NIR fluorescent material, and a preparation method thereof The disclosed polymer particles show magnetic properties and fluorescent properties simultaneously, and thus are useful as contrast agents for NIR/MR bimodal molecular imaging. | 09-01-2011 |
20110201512 | Biomarkers Indicative of Colon Cancer and Metastasis and Diagnosis and Screening Therapeutics Using the Same - The present invention relates to a method for detecting a colon cancer in a human, comprising the steps of: (a) providing a biological sample from the human; and (b) detecting the level of a ATAD2 nucleic acid or a ATAD2 protein in the biological sample, relative to the level of the ATAD2 nucleic acid or the ATAD2 protein in a control sample from a normal human, wherein an increased level of the ATAD2 nucleic acid or the ATAD2 protein in the biological sample compared to the control sample indicates that the human has the colon cancer. The biomarker of this invention was identified using normal colon tissue, colon cancer tissue and metastatic cancer tissue derived from a colon cancer patient. Therefore, the accuracy and reliability of the present biomarker for colon cancer and/or metastasis are much more significantly improved. In addition, the biomarker of this invention permits to identify and predict colon cancer or metastasis in an accurate manner. | 08-18-2011 |
20110201027 | BIOSENSOR FOR DETECTING A TRACE AMOUNT OF SAMPLE AND PRODUCTION METHOD THEREFOR - The present invention relates to a biosensor capable of a trace amount of sample and a fabrication method thereof. More specifically, the invention relates to a method for fabricating a biosensor, the method comprising: immobilizing a receptor molecule, which binds selectively to a target substance, on an electrically insulated nano-electrode chip; binding an enzyme to the receptor molecule; and treating the bound enzyme with metal ions and depositing the metal ions on the nano-electrode surface, and to a biosensor fabricated thereby. According to the invention, a precipitate is produced on the nano-electrode surface by a precipitation between the enzyme and the metal ions, and the produced precipitate electrically connects the nano-electrodes together, thereby increasing electrical conductivity. Thus, the invention is useful for quantitative analysis of trace amounts and/or various concentrations of target substances. | 08-18-2011 |
20110190163 | Genome-Wide Construction of Schizosaccharomyces Pombe Heterozygous Deletion Mutants Containing Gene-Specific Barcodes by the Methods of 4-Round Serial or Block PCR, or Total Gene Synthesis Thereof - A method comprising transforming | 08-04-2011 |
20110189784 | Immunochromatography Detection Sensor Comprising Optical Waveguide and a Detection Method Using the Same - The present invention relates to an immunochromatographic detection sensor comprising optical waveguides and a detection method using the same, and more particularly, to an immunochromatographic detection sensor comprising optical waveguides, in which the optical waveguides are provided under the membrane, probe beams transmitted through the optical waveguide maximize the interaction frequency between evanescent wave generated on the surface of optical waveguide and the colored conjugate in the band formed on the membrane, and thus the absorbance signal from the colored conjugate is greatly amplified to improve the sample detection sensitivity, and a detection method using the same. | 08-04-2011 |
20110171269 | METHOD FOR MANUFACTURING UNIFORM SIZE POLYMERIC NANOPARTICLES CONTAINING POORLY SOLUBLE DRUGS - The present invention relates to a method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs, and more particularly, to a method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs, including a first step of dissolving a biodegradable polymer in a non-volatile polar organic solvent, a second step of adding poorly soluble drugs to water and the biodegradable polymer solution to produce a dispersion, and a third step of adding the dispersion to emulsifier solutions in a batch under the condition of low mechanical energy level stirring. The polymeric nanoparticles of the present invention is capable of manufacturing nano-sized small and uniform polymeric nanoparticles through a simple method of employing a non-volatile polar solvent, especially a solvent having a polarity similar to that of water, as a solvent for a mixture solution of biodegradable polymer and poorly soluble materials, and using a low mechanical energy condition and batch-adding of dispersion in an emulsifying process. The polymeric nanoparticles of the present invention are advantageous in that the dissolution rate of the poorly soluble drugs contained in polymeric particles is dramatically improved, and the poorly soluble drugs are gradually and steadily released and maintained at a constant density over a long period of time. | 07-14-2011 |
20110171097 | FULLERENE-SILICA NANOPARTICLES WITH IMPROVED FLUORESCENCE, PREPARATION METHOD THEREOF AND USE THEREOF - The present invention relates to fullerene-silica nanoparticles with improved fluorescence, a preparation method of the fullerene-silica nanoparticles, and use thereof. More specifically, the present invention relates to fullerene-silica nanoparticles with improved fluorescence in which fullerene and silica are covalently linked, a preparation method of the fullerene-silica nanoparticles, and use thereof. The preparation method of the fullerene-silica nanoparticles comprises the steps of: adding a surfactant to a non-polar organic solvent and a polar solvent and stirring them to form reverse micelles (step 1); adding fullerene to the reverse micelles formed in the step 1 and stirring them (step 2); and adding a silica precursor and a catalyst to a reaction solution containing the fullerene prepared in the step 2 and stirring them to prepare fullerene-silica nanoparticles (step 3). According to the present invention, fullerene-silica nanoparticles in the form of a uniform spherical shape of tens of nanometers can be prepared. As such prepared fullerene-silica nanoparticles have a large surface area due to a nanometer-sized structure, they have good reactivity. Compared with heavy metals or metal nanoparticles, the fullerene-silica nanoparticles, because of using silica, are harmless to a living body. Further, as the fullerene-silica nanoparticles exhibit strong fluorescence, they can be used as a contrast agent for in-vivo imaging or as a drug delivery carrier. | 07-14-2011 |
20110152106 | CST1, DCC1, IFITM1 OR MELK AS MARKERS FOR DIAGNOSING STOMACH CANCER - The present invention relates to a biomarker for gastric cancer, CST1 (cysteine proteinase inhibitor, type 2 family), DCC1 (Defective in sister chromatid cohesion homolog 1), IFITM1 (interferon induced transmembrane protein 1) or MELK (maternal embryonic leucine zipper kinase). More particularly, the present invention relates to a diagnostic composition for gastric cancer comprising an agent measuring the expression level of CST1, DCC1, IFITM1 or MELK, a kit comprising the composition, a method for detecting the marker, and a method for screening a therapeutic agent for gastric cancer using the marker. | 06-23-2011 |
20110110867 | MULTIMODAL IMAGING METHOD USING NANO-EMULSION COMPRISING OPTICAL NANO-PARTICLES AND PERFLUOROCARBONS - The present invention relates to a multimodal imaging method using a nano-emulsion comprising optical nano-particles and perfluorocarbons, and more particularly, to a method of obtaining multimodal images using a nano-emulsion consisted of perfluorocarbons for multispectral magnetic resonance imaging (MRI) and nano-particles for multicolor fluorescent detection. In the multimodal imaging method, various multispectral MRI images and multicolor fluorescent rays can be obtained by varying the kind and combination of perfluorocarbons and the kind and combination of optical nano-particles, so that multiplexed analysis is possible. Accordingly, the multimodal imaging method can be applied to various fields, including biological and medical fields in which studies on cell molecular imaging has been conducted. | 05-12-2011 |
20110065176 | HUMAN MONOCLONAL ANTIBODY NEUTRALIZING VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND USE THEREOF - The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment. | 03-17-2011 |
20110020225 | POROUS POLYMER PARTICLES IMMOBILIZED WITH CHARGED MOLECULES AND METHOD FOR PREPARING THE SAME - The present invention relates to porous polymer particles containing a charged molecule immobilized therein and a method for preparing the same. According to the disclosed invention, porous particles can be prepared using a biocompatible polymer and, at the same time, a charged molecule can be immobilized in the pores of the porous particles, such that various charged molecules can be loaded in the porous particles. In addition, various kinds of drugs or functional materials can be loaded into the porous particles of the present invention by electrostatic attraction and absorption or adsorption by a capillary phenomenon occurring due to porous properties. | 01-27-2011 |
20110014166 | Probiotics Spore-forming Lactic Acid Bacteria SL153 - The present invention relates to the novel | 01-20-2011 |
20100297755 | Method for Differentiating of Human Embryonic Stem Cells Into the Osteoblastic Lineage - Disclosed are a composition for introducing the osteogenic differentiation of human embryonic stem cells and a method for differentiating human embryonic stem cells into an osteoblastic lineage by inhibiting the mTOR signaling pathway. When cultured in the presence of an inhibitor of the mTOR signaling pathway, human embryonic stem cells are effectively induced to differentiate into an osteoblastic lineage. The osteogenic differentiation of human embryonic stem cells using the method and the composition is useful in examining the development and differentiation mechanism of osteoblasts and the cause of metabolic bone diseases, including osteoporosis. In addition, the method and the composition can be applied to the development of osteogenic differentiation techniques for generating clinically useful, terminally differentiated mature cells or progenitor cells. | 11-25-2010 |
20100297694 | NOVEL GENE FROM HANCENULA POLYMORPHA CAPABLE OF CONTROLLING UNFOLDED PROTEIN RESPONSE AND METHOD FOR INCREASING EFFECT OF SECRETION USING THE SAME - The present invention relates to a novel | 11-25-2010 |
20100291248 | Compositions for Preventing and Treating Obesity, Hyperlipidemia, Atherosclerosis, Fatty Liver, Diabetes or Metabolic Syndrome Containing Extracts of Glycine Max Leaves or Fractions Isolated from the Same as an Active Ingredient - The present invention relates to compositions for preventing and treating obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes or metabolic syndrome containing extracts of | 11-18-2010 |
20100286207 | Novel 2-Oxo-Heterocyclic Compounds And The Pharmaceutical Compositions Comprising The Same - The present invention is related to new 2-oxo-cyclic compound, the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the inflammatory disease comprising the pain or inflammation caused by rheumatic disease, for example, rheumatoid arthritis, spondyloarthopathies, gout, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, and inflammatory syndrome for example, from myositis, gingivitis, synovitis, ankylosing spondylitis, burstitis, burns and scar, inflammatory Crohn's disease, Types I diabetes. therefore, it can be used as the therapeutics for treating and preventing inflammatory diseases. | 11-11-2010 |
20100281585 | COMPOSITION AND METHOD FOR INCREASING RESISTANCE AGAINST PLANT PATHOGEN BY COMPRISING BACTERIAL GENETIC MATERIALS, AND PLANT PRODUCED BY THE METHOD - The present invention relates to a composition for increasing resistance to plant pathogen by inducing an immune reaction of a plant wherein said composition comprises bacterial genetic materials as an effective component, a method for increasing resistance to plant pathogen by inducing an immune reaction of a plant wherein said method comprises a step of treating the plant with bacterial genetic materials, a plant produced by mentioned method to have increased resistance to plant pathogen, and seeds of such plant. | 11-04-2010 |
20100279347 | POLYMYXIN SYNTHETASE AND GENE CLUSTER THEREOF - The present invention relates to a polymyxin synthetase isolated from Gram-positive | 11-04-2010 |
20100255500 | IDENTIFICATION METHOD OF GLYCOPROTEINS USING A SPECIFIC LECTIN PRECIPITATION - The present invention relates to an analyzing method of measuring the changes of glycosylation in various glycoproteins which participate in tumorigenesis and metastasis. | 10-07-2010 |
20100248244 | Characterization of ESM-1 as a Tumor Associated Marker of Colorectal Cancer - Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer. | 09-30-2010 |
20100231914 | SURFACE PLASMON RESONANCE SENSOR USING ROTATING MIRROR - Disclosed is a surface plasmon resonance sensor having a rotating mirror, including (a) an incident light source unit for oscillating a laser as incident light; (b) a polarizer for polarizing the incident light; (c) a rotating mirror having cylindrical or planar shapes for reflecting the polarized incident light to radiate disk-shaped light; (d) a light shielding film for allowing part of the disk-shaped light to pass therethrough and located adjacent to the central axis of the rotating mirror; (e) a cylinder lens for focusing the light passed through the light shielding film thereon; (f) a metal thin film for receiving the light focused on the cylinder lens to generate surface plasmon resonance; (g) a dielectric medium provided under the metal thin film; and (h) a detector for detecting the light reflected from the metal thin film. This surface plasmon resonance sensor can solve conventional interference problems of a laser being used as a light source to obtain an image for measurement of angle and two-dimensional reflected light intensity, including the deterioration of the quality of the image and the variation in the intensity of light source depending on the position of incidence. | 09-16-2010 |
20100227362 | Novel YLMPO1 Gene Derived From Yarrowia Lipolytica and A Process for Preparing a Glycoprotein Not Being Mannosylphosphorylated By Using a Mutated Yarrowia Lipolytica in Which YLMPO1 Gene is Disrupted - The present invention relates to a novel YlMPOl gene which plays an important role in mannosylphosphorylation of an industrial yeast | 09-09-2010 |
20100218275 | METHOD FOR INCREASING SALT TOLERANCE OF PLANT BY OVEREXPRESSING SYFBP/SBPASE GENE ISOLATED FROM SYNECHOCYSTIS AND PLANT PRODUCED BY THE SAME - The present invention relates to a method for increasing salt tolerance of a plant by overexpressing SyFBP/SBPase gene isolated from | 08-26-2010 |
20100209945 | METHOD FOR PREPARING ANTIBODY MONOLAYERS WHICH HAVE CONTROLLED ORIENTATION USING PEPTIDE HYBRID - The present invention relates to a method for preparing an protein monolayer using a peptide hybrid for protein immobilization, more precisely a peptide hybrid for protein immobilization which has improved solubility by introducing a PEG linker and a proper reaction group to the oligopeptide having specific affinity to selected types of proteins and is designed to provide enough space between solid substrates and proteins immobilized, whereby various solid substrates treated by the hybrid catch specific proteins effectively on. The peptide hybrid for protein immobilization of the present invention facilitates the control of orientation of an antibody on various solid surfaces and immobilization of various antibodies of different origins or having different isotypes with different affinity. Therefore, the surface treatment technique using the peptide hybrid of the invention can be effectively used for the production of various immunosensors and immune chips. | 08-19-2010 |
20100204444 | MULTIFUNCTIONAL PROTEIN SIMULTANEOUSLY DELIVERING ANTIBODIES AND NANOPARTICLES - The present invention relates to a polypeptide structure which can simultaneously deliver an antibody and a nanoparticle into cells, more specifically, to a polypeptide structure for intracellular delivery of an antibody and a nanoparticle, which comprises a nanoparticle-binding region, an antibody-binding region and a signaling capable of delivering substances into cells. | 08-12-2010 |
20100203510 | PPIA MARKER FOR DIAGNOSIS OF LIVER CANCER AND ANTIBODY, AND SCREENING METHOD OF COMPOUNDS USEFUL FOR INHIBITING LIVER CANCER - Disclosed is a marker for diagnosis of liver cancer comprising polynucleotide useful for diagnosis of liver cancer. The marker for liver cancer diagnosis comprises at least one polynucleotide selected from a group consisting of the following polynucleotides (a) to (d):(a) polynucleotide having a base sequence defined by Seq. No. 1 or substantially similar sequence to Seq. No. 1; (b) polynucleotide encoding specific protein composed of an amino acid sequence defined by Seq. No. 2; (c) polynucleotide that comprises Seq. No. 2, in which at least one amino acid is substituted, deleted, inserted and/or added, and that encodes protein functionally equivalent to specific protein composed of Seq. No. 2; and (d) polynucleotide that is encoded by another polynucleotide hybridized with polynucleotide having Seq. No. 1 under stringent conditions, and that encodes protein functionally equivalent to specific protein composed of Seq. No. 2. | 08-12-2010 |
20100196956 | NOVEL CONSTITUTIVE STRONG PROMOTER AND USE THEREOF - Disclosed herein are an aldolase gene promoter and the use thereof, more particularly, disclosed are a promoter of aldolase gene derived from | 08-05-2010 |
20100196350 | PHARMACEUTICAL COMPOSITION FOR TREATING CHOLANGIOCARCINOMA, A METHOD FOR INHIBITING GROWTH OR INVASION OF CHOLANGIOCARCINOMA AND A METHOD FOR TREATING CHOLANGIOCARCINOMA - Disclosed herein are a pharmaceutical composition for inhibiting the growth or metastasis of cholangiocarcinoiria, comprising a L1CAM activity inhibitor or expression suppressor and a treatment method using the composition. This is based on the finding that L1CAM is overexpressed on cholangiocarcinoma and plays an important role in the growth and metastasis of cholangiocarcinoma and the mortality of cholangiocarcinoma patients increases as the expression rate of L1CAM increases. Also, antibodies inhibitory of the activity of L1CAM, or siRNAs suppressing the expression of L1CAM, are found to reduce the growth and invasion of cholangiocarcinoma cells. Mouse monoclonal antibodies, recognizing the L1CAM protein on the cholangiocarcinoma cell surface and binding specifically to cholangiocarcinoma tissues, or siRNAs, antisense oligonucleotides or shRNAs, may be useful in the treatment of cholangiocarcinoma by inhibiting the growth, invasion and migration of cholangiocarcinoma cell. | 08-05-2010 |
20100159039 | ANTIVIRAL AGENTS CONTAINING A FERMENTATION PRODUCT OF GARLIC BY LACTIC ACID BACTERIA - An antiviral substance including a fermentation product of garlic that is fermented by lactic acid bacteria is provided. More specifically, an antiviral agent including a fermentation product of garlic, that is fermented by lactic acid bacteria, as an active ingredient is provided. The antiviral agent including a fermentation product of garlic fermented by lactic acid bacteria is useful as a preventing or treating agent of viral infection by inhibiting viruses. | 06-24-2010 |
20100159038 | NATURAL ANTIBIOTICS CONTAINING A FERMENTATION PRODUCT OF GARLIC BY LACTOBACILLI - The present invention relates to an antibacterial composition including a fermented garlic solution that is fermented by lactic acid bacteria. More specifically, it provides an antibacterial substance active against gram-positive and gram-negative bacteria, yeast, and antibiotic-resistant bacteria. An antibacterial composition according to the present invention that includes a fermented garlic solution that is fermented by lactic acid bacteria as an active ingredient controls the growth of bacteria or fungi, and is thereby able to prevent and treat infections thereof. | 06-24-2010 |
20100143514 | ANTIVIRAL AGENTS CONTAINING A FERMENTATION PRODUCT OF GARLIC BY LACTIC ACID BACTERIA - An antiviral substance including a fermentation product of garlic that is fermented by lactic acid bacteria is provided. More specifically, an antiviral agent including a fermentation product of garlic, that is fermented by lactic acid bacteria, as an active ingredient is provided. The antiviral agent including a fermentation product of garlic fermented by lactic acid bacteria is useful as a preventing or treating agent of viral infection by inhibiting viruses. | 06-10-2010 |
20100125103 | COMPOSITION FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME CONTAINING OBOVATOL AND ITS SYNTHESIZED DERIVATIVES - Disclosed is a pharmaceutical composition containing obovatol represented by Formula 1 and its derivatives. The obovatol and its derivatives effectively increase the activity of AMPK (AMP-activated protein kinase) that plays an important role in diabetes and metabolic syndrome, and thus may be variously used in treating diabetes and metabolic syndrome. | 05-20-2010 |
20100081638 | COMPOSITIONS COMPRISING AN EXTRACT OF TIARELLA POLYPHYLLA OR COMPOUNDS ISOLATED THEREFROM FOR PREVENTING AND TREATING CANCER DISEASES - The present invention relates to an anoikis-inducing agent comprising a | 04-01-2010 |
20100075962 | INDOL DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC DISORDER CONTAINING THE SAME AS AN ACTIVE INGREDIENT - Disclosed are indole derivatives a preparation method thereof, and a composition for the prevention and treatment of metabolic diseases, containing the same as an active ingredient. The indole derivatives have inhibitory activity against DGAT (diacylglycerol acyltransferase), which causes metabolic diseases such as obesity and diabetes in the process of lipid metabolism. With the ability to effectively control lipid metabolism and energy metabolism, the composition is thus useful in the prevention and treatment of metabolic diseases, such as obesity and diabetes. | 03-25-2010 |
20100062485 | Novel Hansenula Polymorpha Gene Coding for Dolichyl-Phosphate- Mannose Dependent Alpha-1,3 Mannosyltransferase and Process for the Production of Recombinant Glycoproteins With Hansenula Polymorpha Mutant Strain Deficient in - The present invention relates to a process for producing a human-type glycoprotein having reduced glycosylation by genetically manipulating an enzyme involved in glycosylation using a | 03-11-2010 |
20100059726 | MULTICOLOR-ENCODED COLLOIDAL PARTICLES COATED WITH METAL NANOPARTICLES MIXTURE HAVING COLORS IN THE VISIBLE REGION AND METHOD FOR PREPARING THE SAME - The present invention relates to multicolor colloidal particles coated with a metal nanoparticle mixture having colors in the visible region and a method for preparing the same. In particular, relates to a metal nanoparticle mixture in which two or more nanoparticles selected from the group consisting of metal nanoparticles exhibiting red color; metal nanoparticles exhibiting yellow color; and metal nanoparticles exhibiting blue color, are mixed in various compositional ratio, multicolor colloidal particles in which polymer or mineral colloidal particles are coated with the metal nanoparticle mixture, and a method for preparing the same. According to the present invention, all colors that are in the visible region can be developed by suitably mixing metal nanoparticles exhibiting three colors, and multicolor colloidal particles can be prepared by coating polymer or mineral colloidal particles with a metal nanoparticle mixture exhibiting various colors. | 03-11-2010 |
20100056780 | NOVEL O-ACYLOXIME DERIVATIVES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE - The present invention relates to novel O-acyloxime derivatives, a preparation method thereof and a pharmaceutical composition comprising the same for prevention and treatment of cardiovascular disease. | 03-04-2010 |
20100021576 | Bacillus Amyloliquefaciens K317 for Suppressing the Growth of Antibiotics-Resistant Pathogenic Microorganism or Enteropathogenic Microorganism - The present invention relates to a | 01-28-2010 |
20090325972 | NOVEL CINNAMALDEHYDE DERIVATIVES HAVING IMPROVED SOLUBILITY IN WATER, A METHOD FOR PREPARING THE SAME AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed herein are a novel cinnamaldehyde compound represented by Chemical Formula 1 or pharmaceutically acceptable salts thereof. The cinnamaldehyde compound has improved solubility in water and has inhibitory effects on the growth of cancer cells because it induces cell cycle arrest and cell death. Also disclosed are a method of preparing the cinnamaldehyde compound and an anticancer composition including the compound of Chemical Formula 1. | 12-31-2009 |
20090324750 | PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PSEUDOLYSIMACHION LONGIFOLIUM AND THE CATALPOL DERIVATIVES ISOLATED THEREFROM HAVING ANTIINFLAMMATORY, ANTIALLERGIC AND ANTIASTHMATIC ACTIVITY - The present invention relates to a composition comprising an extract of | 12-31-2009 |
20090318376 | High Throughput Screening Method of Binding Inhibitor Between caspase3 and XIAP and Binding Inhibitor Screened Thereby - The present invention relates to a high throughput screening method of a binding inhibitor between caspase3 and xIAP and chromomycin screened using the same, and more specifically, the present invention provides a method for screening anticancer substance, the method comprising the steps of reacting caspase3 or xIAP and candidate inhibitors of the binding between caspase3 and xIAP on a biochip for detecting caspase3:xIAP interaction, and selecting a candidate substance inhibiting the binding of caspase3 to xIAP as an anticancer substance, and an anticancer agent inhibiting caspase3:xIAP binding, which is screened by the above method. According to present invention, it is possible to develop a target-oriented anticancer agent focused on xIAP and caspase3, apoptosis-related proteins and thus it can be applied to tailored medication and combination therapy. Moreover, glycoside antibiotic chromomycin, screened by the present invention has inhibitory activity of the binding between xIAP and caspase3 involved in apoptosis, so that it can be used as a therapeutic agent for myelogenous leukemia and solid tumors. | 12-24-2009 |
20090311354 | COMPOSITION COMPRISING EXTRACTS OR FRACTIONS OF MAGNOLIA OBOVATA THUNB FOR TREATING AND PREVENTING INFLAMMATION DISEASE - The present invention relates to a composition for the prevention and treatment of inflammatory disease containing the extracts of | 12-17-2009 |
20090306078 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT - Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression. | 12-10-2009 |
20090285920 | NATURAL ANTIBIOTICS CONTAINING A FERMENTATION PRODUCT OF GARLIC BY LACTOBACILLI - The present invention relates to an antibacterial composition including a fermented garlic solution that is fermented by lactic acid bacteria. More specifically, it provides an antibacterial substance active against gram-positive and gram-negative bacteria, yeast, and antibiotic-resistant bacteria. An antibacterial composition according to the present invention that includes a fermented garlic solution that is fermented by lactic acid bacteria as an active ingredient controls the growth of bacteria or fungi, and is thereby able to prevent and treat infections thereof. | 11-19-2009 |
20090263521 | COMPOSITION FOR THE TREATMENT OF CANCERS AND INHIBITION OF METASTASIS CONTAINING EXTRACTS OR FRACTIONS OF THE MAGNOLIA OBOVATA - The present invention relates to a composition containing the extracts of | 10-22-2009 |
20090239955 | Novel obovatol derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of cancer containing the same as an active ingredient - Disclosed herein are novel obovatol derivatives represented by Chemical Formula 1, and pharmaceutically acceptable salts thereof. Having the ability to inhibit the growth of cancer cells and induce apoptosis in cancer cells, the derivatives or pharmaceutically acceptable salts thereof are useful in the prevention and treatment of cancer and in the suppression of cancer metastasis. Also, a method for preparing the derivatives, and pharmaceutical compositions comprising the derivatives as active ingredients are disclosed. | 09-24-2009 |
20090181425 | Library of Translational Fusion Partners for Producing Recombinant Proteins and Translational Fusion Partners Screened Therefrom - The invention relates to techniques for the rapid screening of suitable translational fusion partners (TFPs) capable of inducing secretory production of recombinant proteins, especially proteins that are difficult to produce using conventional recombinant production methods. | 07-16-2009 |
20090148542 | Composition comprising an extract of tiarella polyphylla and tiarellic acid isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity - The present invention relates to a composition comprising an extract of | 06-11-2009 |
20090117151 | VECTOR FOR ANTI-HPV VACCINE AND TRANSFORMED MICROORGANISM BY THE VECTOR - Expression vectors that can efficiently produce virion capsid protein, tumor-associated protein of human papillomavirus on a microbial surface. Bacterial strains harboring such surface display vectors, and the use of the bacterial strains or their extracts or purified products as complex vaccines, are also described. The surface display vectors contain one or more than two genes selected from among pgsB, pgsC and pgsA, encoding a poly-χ-glutamic acid synthetase complex (pgsBCA) of a | 05-07-2009 |
20090062384 | NOVEL ABIETANE DITERPENOID COMPOUND, AND COMPOSITION COMPRISING EXTRACT OF TORREYA NUCIFERA, OR ABIETANE DITERPENOID COMPOUNDS OR TERPENOID COMPOUNDS ISOLATED FROM THEM FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE - The present invention relates to a composition for the prevention and the treatment of cardiovascular disease containing extracts of | 03-05-2009 |
20090048328 | Compound Comprising Prodigiosin From Serratia Macescence B-1231 Kctc 0386Bp for Prevention and Treatment of Acute Graft-Versus-Host Disease - This invention relates to a composition for the prevention and treatment of acute graft-versus-host disease comprising prodigiosin isolated from | 02-19-2009 |
20090042872 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same - Disclosed herein are rhodanine derivatives, a method for the preparation thereof, and a pharmaceutical composition containing the same. The rhodanine derivatives have inhibitory activity against protein phosphatases (PPase) such as PTP1B, Prl-3, LAR, CD45, Cdc25A, Cdc25B, Cdc25C, Yop, PP1 and VHR, and can be applied for the prevention and treatment of PPase-caused diseases, including autoimmune diseases, diabetes, impaired glucose intolerance, insulin resistance, obesity, cancers, etc. when the inhibitory activity thereof is modulated. | 02-12-2009 |
20090042188 | Agent for Differentiating Hematopoietic Stem Cell Into Natural Killer Cell Comprising Vdup1 Protein or Gene Encoding the Same, and a Method of Differentiating Hematopoietic Stem Cell Into Natural Killer Cell Using Thereof - The present invention is related to an agent for differentiating hematopoietic stem cell into natural killer cell comprising VDUP1 protein or gene encoding the same, and a method of differentiating hematopoietic stem cell into natural killer cell using thereof. The present invention reveals for the first time that the VDUP1 gene is a critical factor for the regulation of differentiation of natural killer cell by generating a mouse deficient in VDUP1 gene, which confirms that VDUP1 gene is required for NK maturation. Thus, through the regulation of VDUP1 gene, the modulation of NK cells that have ability to kill cancer cells is possible and can be utilized for cell therapeutics. | 02-12-2009 |
20090022765 | COSMETIC PIGMENT COMPOSITION CONTAINING GOLD OR SILVER NANO-PARTICLES - The present invention relates to a cosmetic pigment composition exhibiting colors in the visible region, which comprises an effective amount of nanoparticles or a mixture of two or more nanoparticles selected from the group consisting of (a) gold nanoparticles exhibiting red color; (b) silver nanoparticles exhibiting yellow color; (c) gold-silver alloy nanoparticles exhibiting flame color; and (d) gold nanoparticles exhibiting blue color, and a color cosmetic composition and a color lotion comprising the pigment composition. According to the present invention, it is possible to prepare pigments exhibiting various colors in the visible region using gold or silver nanoparticles, and a cosmetic pigment composition which can exhibit various colors by mixing the pigments in various compositional ratios, in which precipitation or agglomeration of particles does not occur, and whose color can be maintained for a long time. Also, since the pigment of the present invention is not harmful to the human body unlike conventional metal pigments, and contains gold or silver that is beneficial to health, the pigment can be used in various applications as functional raw materials. | 01-22-2009 |
20080312337 | Anticancer Composition Comprising Obovatol or Obovatal - Disclosed herein is an anticancer composition, comprising obovatol, represented by the following Chemical Formula 1, obovatal, represented by the following Chemical Formula 2, and/or pharmaceutical salts thereof. The composition exhibits the activity of inhibiting the growth of cancer cells and suppressing the expression and activity of matrix metalloproteinases (MMPs), and thus can be useful for the prophylaxis and treatment of cancer as well as for the inhibition of cancer metastasis. | 12-18-2008 |
20080305525 | Novel Hansenula Polymorpha Gene Coding for Alpha 1,6-Mannosyltransferase and Process for the Production of Recombinant Glycoproteins with Hansenula Polymorpha Mutant Strain Deficient in the Same Gene - Disclosed are a novel | 12-11-2008 |
20080299238 | NOVEL ABIETANE DITERPENOID COMPOUND, AND COMPOSITION COMPRISING EXTRACT OF TORREYA NUCIFERA, OR ABIETANE DITERPENOID COMPOUNDS OR TERPENOID COMPOUNDS ISOLATED FROM THEM FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE - The present invention relates to a composition for the prevention and the treatment of cardiovascular disease containing extracts of | 12-04-2008 |
20080269158 | E2epf Ubiquitin Carrier Protein-Von Hippel-Lindau Interaction and Uses Thereof - The present invention relates to the E2EPF UCP-VHL interaction and the uses thereof, more precisely a method for increasing or reducing VHL activity or level by regulating UCP activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of UCP activity is accomplished by any UCP activity inhibitor selected from a group consisting of a small interfering RNA (RNAi), an antisense oligonucleotide, and a polynucleotide complementarily binding to mRNA of UCP, a peptide, a peptide mimetics and an antibody, and a low molecular compound. In the meantime, the increase of angiogenesis is accomplished by the following mechanism; UCP over-expression is induced by a gene carrier and thus endogenous VHL is reduced, leading to the stabilization of HIF- | 10-30-2008 |
20080248019 | Recombinant beta-galactosidase derived from Streptococcus pneumaniae - The present invention relates to a novel beta-galactosidase derived from | 10-09-2008 |